◆ ClinicalMetric Research Team · Last Reviewed: May 2026 · Sources: ClinicalTrials.gov · FDA · NIH
◆ Clinical Trial Intelligence — Key Facts
- ✓ 400,000+ active trials registered on ClinicalTrials.gov across 200+ countries (2025)
- ✓ Only ~12% of drugs entering clinical trials ultimately receive FDA approval
- ✓ Average clinical trial takes 6–13 years from Phase 1 to regulatory approval
- ✓ ~40% of trials fail to recruit sufficient participants — the #1 reason trials stop early
- ✓ All trials must register on ClinicalTrials.gov under the FDA Amendments Act (FDAAA 2007)
Patient Guide 30 Questions
Questions to Ask Your Doctor
Before Joining a Clinical Trial
30 essential questions to ask your doctor or clinical trial coordinator before enrolling — covering eligibility, risks, costs, and what to expect.
Key Takeaways
- Your personal physician's clinical judgment matters more than any generic trial evaluation — they know your comorbidities, medication history, and functional status in ways a coordinator cannot assess from a screening call.
- The placebo question is the one most patients forget to ask. In a double-blind 1:1 randomized trial, there's a 50% chance you receive an inactive treatment — know that before you commit, not after you're enrolled.
- Get the cost breakdown in writing before signing the informed consent. The experimental treatment is usually free; ancillary labs, imaging co-pays, non-trial medications, and travel costs may not be.
- Ask for the NCT number and verify it on ClinicalTrials.gov yourself. Legitimate trials are always registered. If it isn't listed, walk away without further discussion.
- Withdrawal is unconditional. Any pressure — explicit or subtle — to remain in a trial is an ethics violation worth reporting directly to the site's Institutional Review Board.
The conversation most patients have with their doctor about clinical trials goes something like this: "There might be a study you could look into." Full stop. No phase information. No explanation of what "randomized" actually means for your odds of receiving the experimental treatment. No discussion of what the visit burden looks like at month six. The questions that determine whether trial participation actually makes sense for your specific situation — your disease stage, treatment history, geography, and the practical constraints of your life — are not generic. Generic questions get generic answers. These thirty questions are designed to get specific ones.
◆ Eligibility & Fit ◈ The Treatment & Protocol ⚠ Risks & Side Effects 📅 Logistics & Commitment $ Costs & Compensation ◎ Results & Your Rights
◆
Eligibility & Fit
5 questions Q1
Am I a good candidate for this trial?
Why ask: Your physician knows your full medical history — comorbidities, prior treatments, functional status — in ways no trial coordinator can from a screening form. Their clinical judgment about fit matters more than any checklist.
Q2
What are the inclusion and exclusion criteria?
Why ask: Criteria exist for scientific and safety reasons that aren't always obvious from the listed text. Understanding each one upfront prevents wasted time and avoids the disappointment of a screen failure you could have predicted.
Q3
Does my current medication or treatment disqualify me?
Why ask: Drug interactions and protocol washout requirements disqualify more patients than most expect. Bring your complete medication list — including supplements — to this conversation.
Q4
Will participating in this trial affect my other treatments?
Why ask: Some trials require stopping current medications or delaying planned procedures. Know the full implications for your existing care before committing.
Q5
Is there a better-suited trial I should consider instead?
Why ask: Your doctor or a trial navigator may know of studies that match your disease stage, molecular subtype, or treatment history better than the trial you've found on your own.
◈
The Treatment & Protocol
5 questions Q1
What exactly will be tested — a drug, device, or procedure?
Why ask: The mechanism of action and delivery method shape the entire risk-benefit calculation. Know what you're actually agreeing to before the consent form appears.
Q2
What phase is this trial? (Phase 1, 2, 3, or 4?)
Why ask: Phase 1 trials are primarily testing safety in small groups with limited efficacy data. Phase 3 trials compare against established treatments in hundreds or thousands of patients. The phase determines how much is known about risks and likely benefits.
Q3
Is there a placebo group? What are the chances I receive placebo?
Why ask: In a double-blind 1:1 randomized trial, you have a 50% chance of receiving an inactive treatment. Some trials use active comparators rather than placebos. This is the question most patients forget to ask and most regret not asking.
Q4
Will I know which group I'm in (blinded vs. open-label)?
Why ask: Blinded trials prevent bias that would compromise the data — but they mean you may not know your treatment assignment during the study. Open-label trials reveal the assignment. This affects both your experience and your ability to make sense of any changes you observe.
Q5
What is the dosing schedule and how is the treatment administered?
Why ask: IV infusions requiring clinic attendance every two weeks are a fundamentally different commitment than an oral tablet taken at home. Understand the delivery method and frequency before you say yes.
⚠
Risks & Side Effects
5 questions Q1
What are the known risks and side effects?
Why ask: You're entitled to a complete picture of potential adverse effects — not a reassuring summary. Ask for the full safety data from any prior phase studies or preclinical work.
Q2
What are the most serious risks?
Why ask: Minor side effects are one conversation. Serious adverse events — even rare ones — are a different conversation. Ask specifically about Grade 3–4 adverse events documented in prior phases.
Q3
How do these risks compare to my standard treatment options?
Why ask: Risk-benefit should always be evaluated relative to your realistic alternatives, not in isolation. An experimental drug with meaningful side effect risk may still be the right choice if standard of care is worse or exhausted.
Q4
What happens if I experience a serious side effect?
Why ask: You need to know the safety monitoring protocols, who to call at 2am with a concern, and whether hospitalization required for a treatment-related adverse event is covered by the sponsor.
Q5
Is there long-term follow-up after the trial ends?
Why ask: Some trials involve years of post-study follow-up visits. Know the full duration of your commitment, not just the active treatment phase.
📅
Logistics & Commitment
5 questions Q1
How many visits are required and how long is each?
Why ask: Screening visits frequently take half a day. Dosing visits vary by protocol. Add up the total time burden over the full study duration, not just the first few months.
Q2
Where will the trial take place? Is travel required?
Why ask: Multi-site trials may allow local participation; single-site studies may require travel to a specific academic center. Geography is a practical eligibility factor that the listing doesn't highlight.
Q3
How long does the trial last?
Why ask: Trials range from weeks to years. Your ability to complete a 36-month commitment depends on factors that have nothing to do with the science — and that's a legitimate consideration.
Q4
Can I continue my normal activities, work, and travel?
Why ask: Some protocols impose restrictions on alcohol, diet, exercise, or international travel. A research trip abroad or a dietary supplement you rely on may conflict with protocol requirements.
Q5
What tests, scans, or procedures will I need to undergo?
Why ask: Beyond the treatment itself, trials often require biopsies, repeated imaging, blood draws, cognitive assessments, or ECGs. Understand the full procedural burden before consenting.
$
Costs & Compensation
4 questions Q1
What costs are covered by the trial sponsor?
Why ask: The experimental drug or device is usually free, but standard care costs — co-pays, ancillary labs unrelated to the protocol, non-trial medications — may not be. Get this breakdown in writing before signing.
Q2
Will my insurance cover trial-related care?
Why ask: Medicare and many private insurers cover routine care costs in approved trials, but coverage varies substantially by plan and state. Verify with your insurer directly — don't rely on the site's general assurance.
Q3
Is there compensation for my time or travel expenses?
Why ask: Many trials reimburse travel, parking, and some offer stipends for time and inconvenience. This information is in the informed consent document; ask about it explicitly.
Q4
What happens to my coverage if I need treatment for a side effect?
Why ask: Under federal regulations, sponsors are responsible for trial-related injury costs — but this is not always communicated clearly. Clarify the financial responsibility chain before any unexpected hospitalization makes the conversation more difficult.
◎
Results & Your Rights
6 questions Q1
Will I be told the results of the trial?
Why ask: Trials don't always share individual-level results. Ask whether you'll receive your personal biomarker or efficacy data, and when aggregate study results will be published.
Q2
Can I continue the treatment after the trial ends?
Why ask: If the treatment is working for you, you'll want to know about compassionate use programs or post-trial access policies before the study ends rather than scrambling afterward.
Q3
Can I withdraw at any time without affecting my regular care?
Why ask: Withdrawal is always unconditional and voluntary. Any pressure — explicit or implicit — to remain in a trial is an ethics violation worth reporting to the site's IRB. Confirm the withdrawal process clearly.
Q4
Who should I contact with concerns or questions during the trial?
Why ask: You should have a specific, named point of contact — typically a study coordinator — available to you throughout participation, including for non-emergency concerns between visits.
Q5
Has this trial been reviewed by an Ethics Board (IRB/IEC)?
Why ask: All legitimate trials require IRB review and approval before initiating. This is your primary ethical safeguard. Ask for the IRB name and confirm the approval status independently if you have any doubts.
Q6
Where can I find the official trial registration?
Why ask: Legitimate trials are registered on ClinicalTrials.gov. Ask for the NCT number and verify it yourself. If a trial can't be found on ClinicalTrials.gov, that is a serious red flag — walk away.
Find Your Trial
Ready to search for clinical trials?
Browse 400,000+ active studies by condition, phase, or location — all from ClinicalTrials.gov.
Related Guides
◆ Primary Sources & Further Reading
→ FDA — Questions Before Joining a Trial
→ NCI — Questions to Ask About Clinical Trials
CM
ClinicalMetric Editorial Verified Publisher
Clinical Trial Research & Intelligence · Est. 2025
This article was researched and written by the ClinicalMetric editorial team using primary sources: ClinicalTrials.gov registry data (NIH/NLM), FDA trial documentation, peer-reviewed literature from PubMed/MEDLINE, and EudraCT (EU Clinical Trials Register). Trial status, eligibility criteria, and enrollment data are sourced directly from official registry APIs — not secondary aggregators.
📅 Last reviewed: 2026-03-01 🔄 Trial data updated daily from ClinicalTrials.gov
◆ Editorial Review Panel
Clinical Trial Research Analyst
ClinicalTrials.gov · FDA registry · trial protocol review
Medical Content Editor
PubMed literature · eligibility criteria · patient safety
Data Accuracy Reviewer
Phase classification · enrollment status · sponsor verification
⚕️ Medical Disclaimer: ClinicalMetric provides research intelligence only. Always consult a qualified healthcare provider before making clinical decisions or participating in a trial.
Publisher
ClinicalMetric
Independent Clinical Trial Intelligence
Tracks 400,000+ active clinical trials worldwide. Updated daily from ClinicalTrials.gov (NIH/NLM), FDA IND registry, and EudraCT (EU Clinical Trials Register).
Research Methodology
Articles are researched from primary registry sources: ClinicalTrials.gov XML feeds, FDA trial databases, and peer-reviewed literature. Trial status, phase, enrollment, and eligibility data is sourced directly from registry APIs — not secondary aggregators.
Primary Data Sources
- ClinicalTrials.gov — NIH/NLM registry
- FDA Clinical Trials
- EudraCT — EU trial register
- WHO ICTRP
- PubMed / MEDLINE — peer-reviewed literature
Accuracy & Updates
Trial status, enrollment, and eligibility information changes frequently. ClinicalMetric syncs with ClinicalTrials.gov daily. Editorial articles are reviewed quarterly or when major protocol amendments are published. Always verify trial status directly on ClinicalTrials.gov before making clinical decisions.
◆ Live Clinical Trial Feed
Browse 400,000+ Active Clinical Trials
Updated daily from ClinicalTrials.gov · Recruiting trials by condition, phase, sponsor
Browse Recruiting Clinical Trials
Find active recruiting trials on ClinicalMetric — updated daily from ClinicalTrials.gov.
Editorial Notice: This article was reviewed by the ClinicalMetric editorial team. Clinical trial data changes frequently as trials progress, enroll, or close. Nothing on this site constitutes medical advice — always consult a qualified healthcare professional. To report an inaccuracy, contact dev@clinicalmetric.com.
◆ Related Research Guides
Trial DesignAdaptive Clinical Trial Design 2026: Seamless Phases, Response-Adaptive Randomization, and Platform TrialsRead guide →Data ScienceAI in Clinical Data Management 2026: EDC, Risk-Based Monitoring, and eTMF AutomationRead guide →PulmonologyAsthma Clinical Trials 2026: Biologics for Severe Asthma & New TreatmentsRead guide →CardiologyAtrial Fibrillation Clinical Trials 2026: New Ablation Techniques, Anticoagulants & Reversal AgentsRead guide →
◆
ClinicalMetric Intelligence Team
Clinical Trial Research & Analysis · Last updated April 2026
Analysis compiled from ClinicalTrials.gov (NIH/NLM), FDA trial registry data, and peer-reviewed clinical research. ClinicalMetric tracks 400,000+ active clinical trials worldwide, updated daily from the ClinicalTrials.gov AACT database.
Get Weekly Clinical Trial Alerts
New recruiting trials from NIH, NCI, and 40+ sponsors — every Monday. Free forever.
◆ Clinical Trial Phase Transition Success Rates
Phase 1 → Phase 2 success ~63%
Phase 2 → Phase 3 success ~32%
Phase 3 → Approval ~58%
Overall FDA approval rate ~12%
Source: Biotechnology Innovation Organization (BIO) Clinical Development Success Rates — approximate industry averages.
◆ Clinical Trial Development Timeline
Mo 1–6
Preclinical + IND Filing
Mo 6–18
Phase 1 (Safety)
Mo 18–48
Phase 2 (Efficacy)
Mo 48–84
Phase 3 (Pivotal)
Mo 84–96
FDA Review / NDA
Mo 96+
Approval + Phase 4
Timeline is approximate. Total development from preclinical to approval averages 6–13 years.
◆
About the Author
ClinicalMetric Research Team
Clinical Trial Intelligence Specialists · clinicalmetric.com
Our analysts monitor 400,000+ clinical trials daily across oncology, neurology, cardiology, and rare diseases. All data sourced from ClinicalTrials.gov and FDA.gov.
🔬 400K+ trials tracked 🌍 200+ countries 🔄 Updated: May 2026
◆ Common Questions About Clinical Trials
Browse by Phase
Browse by Condition
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology